Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (PPE).
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2014
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- Sponsors Schering-Plough
- 24 Jun 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 24 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2009 Planned end date changed from 1 Mar 2009 to 1 Apr 2009 as reported by ClinicalTrials.gov